● Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Janssen Research & Development, LLC

PhasePhase 2

Planned participants480

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

This description comes directly from the study's public registry record.

Talk to the study team

Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com

Always discuss trial participation with your own doctor first.

Locations (202)

Southern Cancer Center, PC	Daphne, Alabama, United States	Recruiting
Clearview Cancer Institute	Huntsville, Alabama, United States	Recruiting
City of Hope Phoenix	Goodyear, Arizona, United States	Recruiting
The Oncology Institute of Hope and Innovation	Cerritos, California, United States	Recruiting
City of Hope Corona	Corona, California, United States	Recruiting
City of Hope	Duarte, California, United States	Recruiting
Providence Medical Foundation	Fullerton, California, United States	Recruiting
Oncology Physicians Network Healthcare	Glendale, California, United States	Completed
Los Angeles Cancer Network	Glendale, California, United States	Recruiting
Glendale Adventist Medical Center	Glendale, California, United States	Recruiting
Marin Cancer Center	Greenbrae, California, United States	Recruiting
City of Hope Seacliff	Huntington Beach, California, United States	Recruiting

+ 190 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06667076